1d
News Medical on MSNFXR cyclic peptide antagonists as a novel strategy for MASH treatmentIn this study, the authors first used an AlphaScreen assay to identify a series of tryptophan-based cyclic peptide compounds with FXR-antagonistic activity, specifically those modified with a ...
Hosted on MSN25d
Treating liver fibrosis and metabolic dysfunction-associated steatohepatitis: Research identifies novel mechanismMetabolic dysfunction-associated steatohepatitis (MASH) significantly increases the ... of the Chinese Academy of Sciences identified a novel mechanism in understanding the therapeutic mechanism ...
OliX is currently developing OLX75016 as a novel therapeutic in treating MASH accompanied by liver fibrosis, and other cardiometabolic indications. Dong Ki Lee, Ph.D., CEO of OliX Pharmaceuticals, ...
Sagimet is a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN ... dysfunction associated steatohepatitis (MASH). FASCINATE-2, a Phase 2b clinical trial of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results